Y Intercept Hong Kong Ltd Acquires 11,827 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

Y Intercept Hong Kong Ltd lifted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 100.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 23,581 shares of the company’s stock after buying an additional 11,827 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Arcus Biosciences were worth $361,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Point72 Hong Kong Ltd acquired a new position in Arcus Biosciences during the third quarter worth $47,000. Innealta Capital LLC acquired a new position in shares of Arcus Biosciences during the 2nd quarter valued at about $66,000. Point72 DIFC Ltd bought a new position in shares of Arcus Biosciences in the 2nd quarter valued at approximately $83,000. Quest Partners LLC lifted its holdings in Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after purchasing an additional 9,408 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in Arcus Biosciences during the third quarter worth approximately $244,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

RCUS has been the subject of a number of analyst reports. Wells Fargo & Company started coverage on shares of Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price objective for the company. HC Wainwright reissued a “neutral” rating and set a $20.00 target price on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Barclays lifted their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Arcus Biosciences currently has a consensus rating of “Buy” and a consensus price target of $34.00.

Arcus Biosciences Trading Up 2.7 %

Shares of RCUS opened at $16.51 on Tuesday. The stock’s 50-day moving average price is $16.52 and its 200 day moving average price is $16.07. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -5.24 and a beta of 0.88. Arcus Biosciences, Inc. has a 12-month low of $13.52 and a 12-month high of $20.31.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.06. The business had revenue of $48.00 million for the quarter, compared to analysts’ expectations of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Arcus Biosciences’s quarterly revenue was up 50.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.94) earnings per share. As a group, research analysts predict that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current year.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.